Role of Tzanck Smear in Determining Pemphigus Vulgaris Disease Activity
Launched by ISTANBUL MEDENIYET UNIVERSITY · Apr 13, 2022
Trial Information
Current as of June 09, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical, histopathological and immunological diagnosis of pemphigus vulgaris
- • Must be active bullae or erosion at any stage of the disease
- Exclusion Criteria:
- • Patients with uncertain diagnosis of pemphigus vulgaris
- • Eroded lesions due to causes other than pemphigus vulgaris (such as herpes in the oral mucosa, candida infection)
About Istanbul Medeniyet University
Istanbul Medeniyet University is a prominent academic institution based in Turkey, dedicated to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive resources and expertise to conduct innovative studies aimed at improving healthcare outcomes. With a strong emphasis on ethical standards and scientific rigor, Istanbul Medeniyet University collaborates with healthcare professionals and researchers to explore new therapeutic strategies and contribute to the global body of medical knowledge. Their commitment to fostering a research-driven environment facilitates the development of cutting-edge treatments and enhances patient care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials